Compound 354
Identifiers
- Canonical SMILES:
FC(F)(F)S(=O)(=O)c1cc(ccc1N[C@H](CCN1CCOCC1)CSc1ccccc1)S(=O)(=O)Nc1ncnc2CN(Cc12)C1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1
- IUPAC name:
N-[6-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
- InChi:
InChI=1S/C45H49ClF3N7O5S3/c46-34-12-10-32(11-13-34)39-9-5-4-6-33(39)27-55-20-17-36(18-21-55)56-28-40-42(29-56)50-31-51-44(40)53-64(59,60)38-14-15-41(43(26-38)63(57,58)45(47,48)49)52-35(16-19-54-22-24-61-25-23-54)30-62-37-7-2-1-3-8-37/h1-15,26,31,35-36,52H,16-25,27-30H2,(H,50,51,53)/t35-/m1/s1
- InChiKey:
MYHAQJLZUQAAHG-PGUFJCEWSA-N
External links
51039416 |
CHEMBL2322029 |
External search
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 72 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 6.01 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 955.26 g/mol | |||
HBA | 12 | |||
HBD | 2 | |||
HBA + HBD | 14 | |||
AlogP | 6.10 | |||
TPSA | 137.07 | |||
RB | 16 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 72 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 6.01 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5382 | Navitoclax | DB12340 | |
0.3875 | Sulfaisodimidine | DB13283 | |
0.3871 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | DB07800 | |
0.3842 | Presatovir | DB12165 | |
0.3785 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3741 | Talotrexin | DB06178 | |
0.3735 | Sparsentan | DB12548 | |
0.3713 | Quinupristin | DB01369 | |
0.3670 | Omidenepag isopropyl | DB15071 | |
0.3646 | GDC-0349 | DB13072 | |
0.3623 | TAK-901 | DB12756 | |
0.3605 | Elobixibat | DB12486 | |
0.3561 | METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE | DB07689 | |
0.3561 | METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE | DB07765 | |
0.3560 | Danusertib | DB11778 |